Your session is about to expire
← Back to Search
Study Summary
This trial is testing a new medication called VX-548 to see if it is effective and safe for treating people with PLSR.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is the eligibility criteria for this medical study inclusive of individuals below the age of 40?
"This clinical trial is seeking participants who are over 18 years of age but under the age of 70."
What is the current number of individuals receiving treatment in this particular research study?
"To successfully conduct this clinical trial, a total of 200 eligible patients are required. Patients from various locations have the opportunity to participate in this study, including JBR Clinical Research located in Salt Lake City, Utah and Arizona Research Center situated in Phoenix, Arizona."
Are individuals currently able to apply and participate in this ongoing research study?
"Indeed, the information available on clinicaltrials.gov indicates that this particular clinical trial is actively seeking eligible participants. The initial posting of the study occurred on December 13th, 2023, and it was most recently updated on January 10th, 2024. A total of 200 patients will be enrolled in this study across eleven different sites."
At how many distinct sites is this clinical trial currently being conducted?
"At present, this clinical trial is accepting patient enrollment at 11 distinct locations. These sites are located in Salt Lake City, Phoenix, Banning, and various other places. For the convenience of participants, it is advisable to choose a site nearest to their location in order to minimize travel obligations."
Has the FDA granted its approval for VX-548?
"Our team at Power has assigned a safety rating of 2 to VX-548, indicating that there is limited data supporting its safety but no evidence yet for efficacy. This assessment aligns with the phase 2 trial design."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger